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Summary
Congenital end-plate acetylcholinesterase (AChE) defi-
ciency (CEAD), the cause of a disabling myasthenic syn-
drome, arises from defects in the COLQ gene, which
encodes the AChE triple-helical collagenlike-tail subunit
that anchors catalytic subunits of AChE to the synaptic
basal lamina. Here we describe a patient with CEAD
with a nonsense mutation (R315X) and a splice-do-
nor–site mutation at position 13 of intron 16
(IVS1613ArG) of COLQ. Because both A and G are
consensus nucleotides at the13 position of splice-donor
sites, we constructed a minigene that spans exons 15–17
and harbors IVS1613ArG for expression in COS cells.
We found that the mutation causes skipping of exon 16.
The mutant splice-donor site of intron 16 harbors five
discordant nucleotides (at 53, 52, 13, 14, and 16)
that do not base-pair with U1 small-nuclear RNA
(snRNA), the molecule responsible for splice-donor–site
recognition. Versions of the minigene harboring, at ei-
ther 14 or 16, nucleotides complementary to U1
snRNA restore normal splicing. Analysis of 1,801 native
splice-donor sites reveals that presence of a G nucleotide
at 13 is associated with preferential usage, at positions
14 to 16, of nucleotides concordant to U1 snRNA.
Analysis of 11 disease-associated IVS13ArGmutations
indicates that, on average, two of three nucleotides at
positions 14 to 16 fail to base-pair, and that the nu-
cleotide at 14 never base-pairs, with U1 snRNA. We
conclude that, with G at 13, normal splicing generally
depends on the concordance that residues at 14 to 16
have with U1 snRNA, but other cis-acting elements may
also be important in assuring the fidelity of splicing.
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Introduction
Acetylcholinesterase (AChE; E.C.3.1.1.7) rapidly hydro-
lyzes acetylcholine (ACh) released at cholinergic syn-
apses. AChE limits the number of collisions between
ACh and the acetylcholine receptor (AChR) and hence
limits the duration of the synaptic response (Katz and
Miledi 1973). Two classes of AChE are present in mam-
malian skeletal muscle (Massoulie´ et al. 1993; Rotundo
and Fambrough 1994): (i) homomeric or globular forms
that consist of monomers (G1), dimers (G2), or tetramers
(G4) of the T isoform of the catalytic subunit (AChET)
and (ii) heteromeric or asymmetric forms that consist of
AChET subunits linked to a collagenlike-tail subunit
composed of three ColQ strands. The function of the
collagenlike tail is to anchor catalytic subunits to the
basal lamina. The proline-rich attachment domain of
each ColQ strand can bind an AChET tetramer, allowing
the formation of asymmetric A4, A8, and A12 moieties
(Bon et al. 1997). Asymmetric AChE is concentrated at
the end plate, where it is the predominant species of
AChE (Hall 1973; Younkin et al. 1982). Congenital end
plate AChE deficiency (CEAD; MIM 603034) results in
a disabling myasthenic syndrome. The prolonged syn-
aptic currents cause repetitive muscle-fiber action po-
tentials, and neither these nor the clinical symptoms are
altered by AChE inhibitors (Engel et al. 1977; Hutch-
inson et al. 1993).
We recently cloned human COLQ cDNA (MIM
603033), determined the structure of the gene, and iden-
tified six recessive truncation mutations in six patients
with CEAD (Ohno et al. 1998b). We also expressed each
mutant COLQ cDNA, along with the wild-typeACHET
cDNA, in COS cells. First, a mutation that truncates
ColQ before the proline-rich attachment domain pre-
vents association of ColQ with AChET. Second, trun-
cation mutations in the collagenic domain of ColQ gen-
erate a mutant ∼10.5 S species of AChE composed of
one AChET tetramer and a truncated ColQ strand. These
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Table 1
Nucleotide Frequencies at 53 to 16 in Human Splice-Donor Sites
SPLICE SITES AND NUCLEOTIDE
% OF NUCLEOTIDE AT POSITION
3 2 1 1 2 3 4 5 6
Total splice sites (1,801 sites)
A 33.3 59.6 8.8 0 0 48.6 72 7.2 15.4
C 36.6 13.4 3.3 0 0 2.6 8.2 4.6 17.3
G 18.4 13.1 80.3 100 0 46.4 11.4 83.3 20.9
T 11.7 13.8 7.5 0 100 2.4 8.4 4.9 46.4
Splice sites with A at position 3 (876 sites)
A 33.7 61.4 10.3 0 0 100 65.5 11.3 18.5
C 37 10 2.7 0 0 0 9.5 7.2 15.6
G 16.8 12.9 78.5 100 0 0 12 72.6 22.5
T 12.6 15.6 8.4 0 100 0 13 8.9 43.4
Splice sites with G at position 3 (835 sites)
A 32.2 55.8 8.1 0 0 0 80.6 3 12.7
C 36.2 17.6 4.2 0 0 0 7.1 2 19.2
G 20 14.1 80.4 100 0 100 9.5 94 18.3
T 11.6 12.5 7.3 0 100 0 2.9 1 49.8
NOTE.—The data were compiled from the GENIO gene database, which represents 1,801 introns of 382 human
multiexon genes. Nucleotides complementary to the 5′ end of U1 snRNA are italicized.
mutations prevent the assembly of the normal asym-
metric forms of AChE. Donger et al. (1998) also cloned
COLQ cDNA and reported a recessive missense mu-
tation in the C-terminal region of ColQ that caused par-
tial CEAD without preventing the assembly of the nor-
mal asymmetric forms of AChE. Feng et al. (1999)
recently reported that ColQ-deficient mice exhibit ab-
normalities similar to those observed in patients with
CEAD.
Here we trace a case of CEAD to two heterozygous
mutations in the C-terminal region of ColQ: a nonsense
mutation (R315X) and a splice-donor–site mutation
(IVS163ArG). Since the intron nucleotide at 3 is an
A in 49% and a G in 46% of human genes (see table
1), we constructed a COLQ minigene that spans exons
15–17 and harbors IVS163ArG. Expression of the
minigene in COS cells revealed that IVS163ArG
causes skipping of exon 16. Critical examination of the
nucleotides surrounding IVS163 in COLQ, of other
disease-associated ArG mutations at position 3, and
of native splice-donor sites leads to the conclusion that,
with G at position3, normal splicing generally depends
on concordance of residues at 4 to 6 with U1
snRNA, the molecule responsible for splice-donor–site
recognition (Mount et al. 1983).
Patient and Methods
Patient
A 46-year-old male had had both progressive weak-
ness increased by exertion and difficulty in walking, since
age 8 years. On examination at age 43 years, the patient
had weakness of facial, respiratory, neck, and proximal-
limb muscles. An electromyogram showed a decremental
response on repetitive stimulation and a repetitive com-
pound muscle-fiber action potential in response to a sin-
gle nerve stimulus. The patient has no anti–acetylcholine
receptor (AChR) antibodies, and neither his physiolog-
ical abnormalities nor his symptoms respond to AChE
inhibitors. His two sisters are similarly affected. His par-
ents are unaffected.
Mutation Analysis
Genomic DNA was isolated from proteinase/SDS di-
gestion of blood (Sambrook et al. 1989). Since a repet-
itive compound muscle-action potential can also occur
in the slow-channel congenital myasthenic syndrome
caused by a mutation in an AChR subunit gene, we first
sequenced all 44 exons of four AChR subunit genes, as
well as their flanking regions (Ohno et al. 1995), but we
identified no mutation. We next sequenced the 17 con-
stitutive and 2 alternatively transcribed exons, as well
as their flanking regions in COLQ (Ohno et al. 1998b).
Sequencing analysis was performed with an ABI 377
DNA sequencer (Perkin-Elmer).
For tracing the R315X mutation in family members,
we amplified a 342-bp fragment of COLQ, using prim-
ers 5′-AGGCATACCCTGAAATGCTG-3′, in intron 12,
and 5′-GGATTTTACAAAGCCCCATA-3′, in intron 13.
The R315X mutation results in loss of an AciI site (New
England Biolabs), so that the wild-type allele gives rise
to 249- and 93-bp fragments, whereas the mutant allele
remains undigested.
For tracing IVS163ArG in family members and in
100 normal controls, we employed allele-specific PCR.
The sense primer was 5′-AGGGGTGCAGCACTTA-
Ohno et al.: Splice-Donor Site Mutation in COLQ 637
Figure 1 Construction of a minigene spanning exons 15–17.
Three PCR products were amplified from genomic DNA to include
exons 15–17. The PCR products were digested with BamHI (B) and
SacI (S), and ligated to make a minigene. Unblackened boxes show
exons and their numbers. Hatched areas indicate 3′ noncoding region.
Exons and introns are drawn to scale.
GGT-3′. The respective wild-type and mutant antisense
primers were 5′-GAGGGAGGGGAGTCATCgCT-3′ and
5′-GAGGGAGGGGAGTCATCgCC-3′, where “g” rep-
resents a deliberately introduced mismatch to avoid an-
nealing of the primer to the opposite allele. The size of
the expected PCR product was 235 bp.
Construction of Minigenes to Analyze Aberrant
Splicing
To evaluate the effects that IVS163ArG has on pre-
mRNA splicing, we constructed a COLQ minigene
spanning exons 15–17 (fig. 1). Since introns 15 and 16
are large (∼2.4 and ∼2.9 kb, respectively), we trimmed
the intronic sequences. Three DNA fragments were am-
plified from control genomic DNA to include exons 15,
16, and 17, respectively, using the Expand High Fidelity
PCR System (Boehringer Mannheim). The three PCR
products were mixed and double-digested with BamHI
and SacI (Boehringer Mannheim). BamHI recognition
sites are at IVS15229 and IVS1590. SacI recognition
sites are at IVS16266 and IVS16322. The restriction
fragments were purified with the QIAquick PCR Puri-
fication Kit (Qiagen) to eliminate small restriction frag-
ments and then were ligated at the BamHI sites in intron
15 and at the SacI sites in intron 16. Ligated products
were used as a template for the second-step PCR with
one primer located within exon 15 and the other in the
3′ noncoding region of exon 17. The PCR product was
excised from 1% SeaPlaque agarose gel (FMC Bio-
Products), purified with the Wizard PCR Preps (Pro-
mega), and ligated to pGEM-T vector (Promega). The
entire insert was sequenced to confirm that the expected
fragment was cloned and that there was no PCR artifact.
The insert was then transferred to the cytomegalovirus-
based expression vector, pRBG4 (Lee et al. 1991).
Next, we introduced IVS163ArG into the minigene
in pRBG4, using the QuickChange Site-Directed Mu-
tagenesis kit (Stratagene). We similarly introduced C, A,
A, and T nucleotides at positions 3, 2, 4, and 6,
respectively. The presence of the desired mutations and
the absence of unwanted mutations were confirmed by
sequencing the entire insert.
Transfection of Minigene Constructs into COS Cells
and Reverse-Transcription–PCR Analysis of
Cytoplasmic RNA
COS-7 cells were transfected, 1 d after plating, by the
DEAE-dextran method (Selden et al. 1986) with 1 mg of
a minigene construct per 35-mm dish. The cells were
collected 3 days after transfection, and cytoplasmic RNA
was extracted by the RNeasy Mini kit (Qiagen), ac-
cording to the manufacturer’s instructions. Isolated
RNA was treated with 40 units of DNase to eliminate
plasmid DNA and was purified again with the RNeasy
Mini kit. One-third of the isolated cytoplasmic RNA was
used for cDNA synthesis with an oligo-dT primer and
the cDNA Cycle kit (Invitrogen). One-tenth of the syn-
thesized cDNA was used for RT-PCR with primer 5′-
CAGCTGACCCCTTTCTACCC-3′ in exon 15 and with
primer 5′-AGCGGCAGGGCGTGGAGT-3′ in exon 17.
With these primers, a normal transcript would yield a
286-bp fragment, whereas a transcript skipping exon 16
(103 bp) would give rise to a 183-bp fragment.
Faint bands below the aberrantly transcribed 183-bp
fragment were excised from 4% NuSieve agarose (FMC
Biolabs), purified with the Wizard PCR Preps, and li-
gated into pGEM-T vector. To determine the origin of
the faint bands, eight pGEM-T clones were sequenced.
Expression Studies of AChE Molecules in COS Cells
In a study reported elsewhere (Ohno et al. 1998b),
we cloned human ACHET cDNA and COLQ cDNA and
introduced them into the pTargeT expression vector
(Promega). We engineered R315X into COLQ cDNA,
using the QuickChange Site-Directed Mutagenesis kit.
To eliminate exon 16 from COLQ cDNA, we used the
aberrant transcript that skips exon 16 (see Results). The
RT-PCR product amplified from the aberrant transcript
served as a megaprimer for the megaprimer-based mod-
ification of the QuickChange Site-Directed Mutagenesis
kit (Ohno et al. 1998a). The presence of the desired
mutation and the absence of unwanted mutations were
confirmed by sequencing the entire insert.
COS-7 cells were transfected, 1 d after plating, by the
DEAE-dextran method with 5 mg of AChET cDNA and
5 mg of DNA, encoding the wild-type or mutant COLQ
cDNA, per 10-cm dish. We extracted AChE molecules
3 d after transfection, fractionated AChE in a 5%–20%
sucrose density gradient, and determined AChE activity
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Figure 2 Schematic presentation of positions of COLQ muta-
tions. Both R315X and IVS163ArG are at the C-terminal region.
Arrows point to the C-terminal end of the wild-type residues.
-rich attachment domain to bind AChET tetramer;PRAD = proline
sulfate proteoglycan-binding domain to anchorHSPBD = heparan
ColQ in the synaptic basal lamina.
Figure 3 Restriction analysis of PCR products and allele-specific
PCR (ASP) of genomic DNA isolated from blood of nuclear family
members. The R315X mutation results in loss of an AciI site. The
wild-type allele gives rise to 249- and 93-bp fragments, whereas the
mutant allele remains undigested at 342 bp. The 93-bp fragment is
not shown. The IVS163ArG mutation is detected by ASP. Blackened
symbols represent affected individuals; half-blackened symbols rep-
resent asymptomatic carriers. Unblackened and blackened arrowheads
indicate wild-type and mutant fragments, respectively.
in the gradient fractions, by the Ellman method (Ohno
et al. 1998b).
Analysis of 1,801 Native Splice-Donor Sites in
Humans and of 10 Additional Disease-Associated
ArG Mutations at Position 3
The GENIO database, a nonredundant gene database
derived from GenBank release 102, lists 382 multiexon
genes in humans (see Electronic-Database Information).
These genes harbor 1801 introns, and we extracted
1,801 splice-donor–site sequences at positions3 to6
from these introns.
Disease-associated ArG mutations at position 3
have been reported at 10 splice-donor sites of eight hu-
man genes. For seven mutations, we obtained the splice-
donor–site sequences at positions 3 to 6 either di-
rectly from published reports or from the gene database
(Higuchi et al. 1990; Carstens et al. 1991; Bidichandani
et al. 1994; Purandare et al. 1994; Brackett et al. 1995;
Richard et al. 1995; Zolezzi et al. 1997). For two mu-
tations in the retinitis pigmentosa GTPase regulator
(RPGR) gene, splice-donor–site sequences of introns 4
and 10 were kindly provided by A. Swaroop (Burac-
zynska et al. 1997; Fujita et al. 1997). For a mutation
in the ferrochelatase gene, we determined the entire se-
quence of intron 10, using published PCR primers (Wang
et al. 1995).
Results
Mutation Analysis
Direct sequencing of the 17 constitutive and 2 alter-
natively transcribed COLQ exons and their flanking
regions revealed two heterozygous mutations in the C-
terminal region of ColQ (fig. 2). The first mutation is a
CrT transition at nucleotide 943, which converts an
arginine codon to a TGA stop codon at position 315
(R315X). R315X eliminates 86% of the residues of the
C-terminal region. The second mutation is an ArG tran-
sition at the third nucleotide of the splice-donor site of
intron 16 (IVS163ArG). IVS163ArG was not
found in 100 normal controls. Three affected siblings
carry both mutations. Unaffected family members are
either heterozygous for a single mutation or carry no
mutation (fig. 3). Thus, the two mutations are hetero-
allelic and recessive.
Reverse-Transcription–PCR Analysis of COS Cells
Transfected with Minigenes
Since both A and G nucleotides are commonly ob-
served at position 3 of native splice-donor sites in hu-
mans, an ArG substitution at position 3 could be a
rare polymorphism. We therefore analyzed the effects of
IVS163ArG on pre-mRNA splicing, by examining
COS cells transfected with a minigene construct har-
boring either the wild-type A or the mutant G nucleotide
at position 3. RT-PCR of cytoplasmic RNA isolated
from transfected COS cells shows that the wild-type
splice-donor site of intron 16 results in normal splicing
plus trace amounts of an aberrant transcript that skips
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Figure 4 Size fractionation of RT-PCR products amplified from
cytoplasmic RNA of COS cells transfected with minigene constructs
harboring the indicated splice-donor–site sequences at the exon16/
intron16 boundary of COLQ. The 286-bp band represents a normal
transcript; the 183-bp band represents an aberrant transcript that skips
exon 16. Faint 164- and 153-bp bands in lanes 2 and 3 are due to
activation of cryptic splice sites in exon 15 (see fig. 5). Uppercase and
lowercase letters indicate, respectively, accordant and discordant nu-
cleotides for U1 snRNA. The patient’s mutation and artificial nucle-
otide substitutions are underlined. Lane 1, Wild-type COLQ. Lane 2,
IVS163ArG in the patient. Lane 3, IVS163ArG plus a TrC sub-
stitution at 3. Lane 4, IVS163ArG plus a GrA substitution at
2. Lane 5, IVS163ArG plus a GrA substitution at 4. Lane 6,
IVS163ArG plus a GrT substitution at 6.
Figure 5 Nucleotide sequence of intron/exon boundaries of the
wild-type COLQ. Boldface letters indicate invariant GT or AG din-
ucleotides at the native or cryptic splice sites. The activated cryptic
splice sites are 30- and 19-bp upstream to the native splice-donor site
in intron 15. The consensus value (see Discussion) for each splice site
is shown above the invariant dinucleotide. Note that the consensus
values for the cryptic splice sites are as high as that of the native splice-
donor site in intron 15.
exon 16 (fig. 4, lane 1). By contrast, IVS163ArG
yields a transcript with skipped exon 16 plus trace
amounts of normal transcript (fig. 4, lane 2). Skipping
of exon 16 eliminates 34% of the native residues of the
C-terminal region and results in 57 missense codons fol-
lowed by a stop codon. We previously reported seven
alternative COLQ transcripts but none with skipped
exon 16 (Ohno et al. 1998b). Thus, that some skipping
of exon 16 occurs with the normal minigene either is
due to the heterologous expression system or is peculiar
to the minigene. A low consensus value of the native
splice-donor site of intron 16 could also contribute to
the aberrant splicing (fig. 5). That some normal tran-
script is detected with the IVS163ArG mutant may
or may not be unique to the heterologous expression
system employing a minigene. It is also possible that
traces of the normally spliced transcript are expressed
at the patient’s end plates, which would mitigate the
consequences of the splice-site mutation.
We also detected faint bands below the aberrant tran-
script that skips exon 16 (fig. 4, lanes 2 and 3). Se-
quencing of the cloned faint bands revealed activation
of two cryptic splice sites within exon 15 (fig. 5). The
activated cryptic splice sites are 30 and 19 bp upstream
of the native splice-donor site of intron 15. The acti-
vation of cryptic splice sites is likely due to the low
consensus value of the native splice-donor site of intron
15 (Krawczak et al. 1992; Nakai and Sakamoto 1994).
Since both cryptic splice sites result in frameshifts, these
aberrant transcripts cannot mitigate the consequences of
skipped exon 16.
We next asked why a G nucleotide at position 3
causes aberrant splicing in COLQ, even though the con-
sensus nucleotide at position 3 is either an A or a G.
The wild-type sequence of the splice-donor site of
COLQ intron 16 is tgG\GTAgGg, where the lowercase
letters at positions 3, 2, 4, and 6 represent dis-
cordant nucleotides against the 5′ end of U1 snRNA (fig.
6). The mutant splice-donor site, tgG\GTggGg, harbors
five discordant nucleotides, at positions 3, 2, 3,
4, and 6. We hypothesized that the number of dis-
cordant nucleotides in the mutant donor site exceeds the
critical threshold and that the positions of the discordant
nucleotides play a pivotal role in skipping of exon 16.
To test this notion, we engineered accordant nucleotides
at positions 3, 2, 4, and 6, one by one, into the
construct that contained IVS163ArG and transfected
them into COS cells (fig. 4, lanes 3–6). Introduction of
the accordant C nucleotide at position 3 did not pre-
vent aberrant splicing (fig. 4, lane 3). Introduction of
the accordant A nucleotide at position 2 partially re-
stored normal splicing (fig. 4, lane 4). Interestingly, a
GrA substitution at position 4 completely rectified
aberrant splicing (fig. 4, lane 5). This artificial construct
functioned even better than the wild-type construct,
since we detected no skipping of exon 16. Introduction
of the accordant T nucleotide at position 6 also pre-
vented aberrant splicing (fig. 4, lane 6). To summarize,
in the presence of IVS163ArG, introduction of an
accordant nucleotide at position 3 or 2 has no or
little beneficial effect, whereas introduction of an ac-
cordant nucleotide at position 4 or 6 completely
abolishes aberrant splicing. This implies that both the
number and position of accordant nucleotides determine
normal splicing. Therefore, a G nucleotide at position
3 is acceptable at the splice-donor site of intron 16 of
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Figure 6 Schematic presentation of base pairing between the 5′
end of U1 snRNA and the wild-type splice-donor site of COLQ intron
16. Short vertical lines between the two molecules represent hydrogen
bonds. Uppercase and lowercase letters indicate accordant and dis-
cordant nucleotides, respectively.
Figure 7 Sedimentation profiles of AChE species extracted from
COS cells transfected with the indicated COLQ cDNA along with the
wild-type ACHET cDNA. G1, G2, and G4 are globular forms; A4, A8,
and A12 are asymmetric forms; M is a ∼10.5 S mutant peak composed
of a catalytic tetramer bound to a truncated single strand of ColQ.
COLQ only when at least two of three nucleotides at
positions4 to6 are complementary to the U1 snRNA
sequence.
Expression Studies of AChE Molecules in COS Cells
We next investigated the effects of two COLQ mu-
tations on the expression and assembly of the AChE
molecules. We transfected wild-type COLQ cDNA or
mutant COLQ cDNA harboring either R315X or
skipped exon 16, along with the wild-type ACHET
cDNA. Extracts of COS cells transfected with wild-type
ACHET and wild-type COLQ show three asymmetric
forms (A12, A8, and A4) and three globular forms (G4,
G2, and G1) (fig. 7, top), as described elsewhere (Ohno
et al. 1998b). Cotransfection of the R315X mutant with
the wild-type ACHET produces low peaks of the asym-
metric and globular species of AChE and a prominent
∼10.5 S mutant (M) peak composed of a catalytic tet-
ramer and a truncated single strand of ColQ (Ohno et
al. 1998b) (fig. 7, center). The sedimentation coefficient
of the ∼10.5 S mutant peak is slightly greater than that
of G4 peak (Ohno et al. 1998b), and, therefore, the mu-
tant peak may include a small contribution from the G4
peak. Cotransfection of the COLQ mutant harboring
skipped exon 16 along with the wild-type ACHET pro-
duces a sedimentation profile similar to that obtained
after cotransfection of the wild-type COLQ and wild-
type ACHET (fig. 7, bottom), but the ∼10.5 S peak is
slightly higher than the wild-type G4 peak, suggesting
that a small amount of the ∼10.5 S mutant species might
also be present.
Discussion
AChE Molecules Formed in COS Cells
We have described two heterozygous truncation mu-
tations in the COLQ gene in a patient with CEAD. The
R315X mutation eliminates 86% of the C-terminal re-
gion of ColQ. The IVS163ArG mutation causes fra-
meshifting skipping of exon 16, which eliminates 34%
of the C-terminal region of ColQ.
Expression of the R315X mutant with the wild-type
ACHET reveals reduced asymmetric and globular forms
of AChE and a prominent ∼10.5 S mutant peak con-
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Table 2
Effect that Nucleotide at Intron Position 13 Has on Complementarity to U1 snRNA
NUCLEOTIDE AT POSITION 3
NO. OF
SITES
MEAN  SD CV (AND DN) AT SEGMENTa
3 to 1 4 to 6 3 to 6
Any nucleotide 1,801 .728  .289 (1.2  .9) .737  .277 (1.2  .9) .843  .087 (2.2  .9)
Native A 876 .726  .296 (1.2  .9) .660  .306 (1.2  .9) .825  .088 (2.4  .9)
Native G 835 .715  .288 (1.3  .9) .821  .213* (.8  .7*) .867  .078* (3  .9*)
Mutant G 11 .839  .172 (.9  .7) .343  .227* (2  .6*) .753  .074* (3.9  1*)
* ; native G is compared to native A; mutant G is compared to native G.P ! .005
a value; of discordant nucleotides.CV = consensus DN = number
sisting of a single ColQ strand attached to an AChET
tetramer (fig. 7, center). Formation of triple-helical ColQ
clusters positive charges at heparan sulfate proteoglycan
binding domains and is essential for anchoring the col-
lagenlike tail to the basal lamina (Deprez and Inestrosa
1995). Therefore, the single-stranded ∼10.5 S mutant
species is unlikely to be anchored to the synaptic basal
lamina. Moreover, we have shown elsewhere that no
AChE is anchored to the synaptic basal lamina with
truncation mutations in the collagenic domain of ColQ
that produce prominent ∼10.5 S peaks (Ohno et al.
1998b). The small amount of asymmetric A4, A8, and
A12 species detected with this mutation may not be suf-
ficient to effect hydrolysis of ACh at the synapse; in
addition, truncation of the C-terminal region of ColQ
likely prevents anchoring of the asymmetric species to
the basal lamina.
The IVS163ArG mutation causes skipping of exon
16. Expression of COLQ cDNA lacking exon 16 with
the wild-type ACHET cDNA indicates that the skipped
exon 16 does not prevent the assembly of the asymmetric
species of AChE (fig. 7, bottom). Therefore, the AChE
deficiency at the end plate must owe entirely to a defect
in the anchoring of the truncated asymmetric species to
the basal lamina. Casanueva et al. (1998) recently re-
ported that two collagenous polypeptides (140 and
195–215 kD) in the synaptic basal lamina bind asym-
metric AChE, but the binding domain(s) in ColQ were
not identified. Additional studies will be required to de-
termine whether the C-terminal region of ColQ binds to
these polypeptides.
That more asymmetric species of AChE are formed
when exon 16 of COLQ is skipped than when the
R315X mutant is present may be because of preservation
of a longer stretch of the C-terminal region with the
former mutation, for the C-terminal region of ColQ, like
that of other collagen molecules, likely promotes the
triple-helical association of individual collagen strands
(Do¨lz et al. 1988; Prockop and Kivirikko 1995). It is
interesting to note, however, that only 14% of the C-
terminal region is able to induce triple-helical association
of ColQ, although at a markedly reduced efficiency
(compare top and center panels of fig. 7). On the other
hand, when 66% of the C-terminal region is retained,
the triple-helical association of ColQ is unhindered
(compare the top and bottom panels of fig. 7).
How Does a G Nucleotide at Intron Position 3
Result in Aberrant Splicing?
The IVS163ArG mutation is intriguing because
both A and G nucleotides are commonly observed at the
3 position of native splice-donor sites in humans (table
1). Several site-directed mutagenesis studies have inves-
tigated the effects of the splice-donor–site sequence on
splicing (Grabowski et al. 1991; Kuo et al. 1991; Kister
et al. 1993; Tsukahara et al. 1994), but none has ad-
dressed the consensus A and G nucleotides at 3. Our
transfection experiments using minigene constructs in-
dicate that accordant nucleotides at positions 4 and
6 in intron 16 restore normal splicing when the nu-
cleotide at intron position 3 is G, whereas accordant
nucleotides at position 3 or 2 in exon 16 had no or
little effect on splicing (see fig. 4). To evaluate the gen-
erality of this observation, we examined the nucleotide
frequencies at positions 3 to 6 of the 1,801 native
splice-donor sites of 382 human multiexon genes (table
1). When the nucleotide at position 3 is G, the fre-
quencies of accordant nucleotides at positions4 to6
are higher than those observed in splice-donor sites with
A at position 3. On the other hand, the frequencies of
the accordant nucleotides at positions 3 to 1 do not
depend on whether position 3 is occupied by an A or
a G nucleotide. It is interesting to note that the frequency
of an accordant T at 6 is only slightly higher with G
at 3 than with A at 3, whereas the introduction of
a T at 6 restores normal splicing in our transfection
experiments. This may imply that, for fidelity of splicing,
the number of accordant nucleotides at4 to6 is more
crucial than their position.
Next, using 1,801 human slice donor sites, we cal-
culated the consensus values (CVs) at positions 3 to
1 (CV3 to 1), positions 4 to 6 (CV4 to 6), and all
positions from 3 to 6 (CV3 to 6), in two categories
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Table 3
ArG Mutations at Intron Position 13
Gene Mutated Sequencea Intron Reference
Coagulation factor VIIIb CAG:GTgtGT 6 Bidichandani et al. 1994
Coagulation factor VIIIc CAG:GTgtGa 14 Higuchi et al. 1990
Ornithine transcabamylased gAG:GTgtGc 7 Carstens et al. 1991
Collagen a2Id CgG:GTggGT 26 Zolezzi et al. 1997
b-hexosaminidase Ad CtG:GTgtGa 8 Richard et al. 1995
Trifunctional protein ad aAG:GTgtcT 3 Brackett et al. 1995
Ferrochelatased aAG:GTgtcT 10 Sarkany and Cox 1995; Wang et al. 1995
Neurofibromind tAG:GTgtaT 11 Purandare et al. 1994
RPGRd CAG:GTgtag 4 Buraczynska et al. 1997
RPGRe agG:GTgcaa 10 Fujita et al. 1997
COLQd,e tgG:GTggGg 16 Present study
a Uppercase and lowercase letters indicate, respectively, complementarity and discordance with regard
to U1 snRNA. Colons indicate exon/intron boundaries.
b Exons 5 and 6 are skipped.
c mRNA is not analyzed.
d Preceding exon is skipped.
e Cryptic splice site is activated.
with A and G at position 3 (table 2). The CV reflects
the similarity of a given splice site to the consensus se-
quence deduced from a comprehensive collation of na-
tive genes (Shapiro and Senapathy 1987). Consistent
with the observations in table 1, CV4 to 6 with G at
position 3 is significantly higher, and the number of
discordant nucleotides is significantly lower, than the
corresponding values with A at position 3.
Ten disease-associated ArG splice-donor–site muta-
tions have been reported at intron position 3,
and aberrant splicing was documented for nine of these
mutations (table 3). Including the currently reported
IVS163ArG, calculation of CVs at 11 mutant splice-
donor sites reveals that the CV4 to6 of the mutant sites
is significantly lower, and that the number of discordant
nucleotides is significantly higher, than it is with a native
G at position 3 (table 2). Ketterling et al. (1999) re-
cently proposed that splice-donor–site mutations not in-
volving GT-invariant nucleotides cause disease when
only five or six of eight nucleotides at 2 to 6 match
the consensus sequence (the “5-6 hypothesis”). Of 11
ArG mutations at 3, 10 conform to this hypothesis.
Our studies also point to the positional significance of
accordant nucleotides at splice-donor sites.
Interestingly, at all 11 mutant splice-donor sites the
nucleotides at position 4 are always discordant (table
3). A T nucleotide is used at position 4 at 8 of 11
mutant sites, yet T is the least frequent nucleotide at this
position in native splice sites when G is at 3 (table 1).
Indeed, the “GT” dinucleotides at positions 3 and 4
are the only discordant nucleotides in the mutant splice-
donor site of intron 6 of the coagulation factor VIII gene
(Bidichandani et al. 1994). Therefore, discordance of
nucleotides at positions 3 and 4 may be necessary
for aberrant splicing. Discordance at 3 and 4 alone,
however, may not be sufficient for aberrant splicing, be-
cause a similar minigene construct in our expression sys-
tem resulted in normal splicing (see fig. 4, lane 6), and
because discordant nucleotides at 3 and 4 were ob-
served at 11% of native splice-donor sites. That there is
no critical threshold in the splice-donor–site sequence
that differentiates normal from aberrant splicing implies
that additional cis-acting elements also play a role in
assuring the fidelity of splicing. The additional cis-acting
elements in splicing include a splice-acceptor site in the
preceding intron (Berget 1995), polypyrimidine tract
(Roscigno et al. 1993; Anderson and Moore 1997), in-
tronic (A/U)GGG consensus sequence (Sirand-Pugnet et
al. 1995), branch-point sequence (Berglund et al. 1997),
exonic splicing enhancers (Watakabe et al. 1993; Tanaka
et al. 1994), secondary structures at the splice site
(Clouet d’Orval et al. 1991), and exon size (Dominski
and Kole 1991, 1992). For example, suppressor muta-
tions remote from the splice-donor site can rescue ab-
errant splicing caused by splice-donor–site mutations at
positions 3, 4, or 5 in the dihydrofolate reductase
gene (Carothers et al. 1993). Zhang (1998) recently re-
ported that A, rather than G, is preferentially used at
3 at human splice-donor sites at low GC loci; this
also implicates exonic cis-acting elements in splicing.
The importance of discordance of a G nucleotide at
intron position 3 to U1 snRNA has been underesti-
mated, because both A and G at 3 are consensus nu-
cleotides. Our findings imply that nucleotides at 4 to
6 need to be accordant to U1 snRNA when there is a
G nucleotide at 3. Our observations should also help
to determine whether an ArG substitution at position
3 is a mutation or a polymorphism and should aid in
the search for exons in human genomic sequences.
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